

<https://helda.helsinki.fi>

Breaking the epithelial polarity barrier in cancer: the strange case of LKB1/PAR-4

Partanen, Johanna I.

2013-11-05

Partanen , J I , Tervonen , T A & Klefstrom , J 2013 , ' Breaking the epithelial polarity barrier in cancer: the strange case of LKB1/PAR-4 ' , Philosophical Transactions of the Royal Society. Biological Sciences , vol. 368 , no. 1629 , 20130111 . <https://doi.org/10.1098/rstb.2013.0111>

<http://hdl.handle.net/10138/302492>
<https://doi.org/10.1098/rstb.2013.0111>

unspecified
publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Review



Cite this article: Partanen JI, Tervonen TA, Klefström J. 2013 Breaking the epithelial polarity barrier in cancer: the strange case of LKB1/PAR-4. *Phil Trans R Soc B* 368: 20130111. <http://dx.doi.org/10.1098/rstb.2013.0111>

One contribution of 17 to a Discussion Meeting Issue 'Cellular polarity: from mechanisms to disease'.

Subject Areas:

molecular biology, cellular biology,
health and disease and epidemiology

Keywords:

LKB1, hepsin, basement membrane,
cell polarity, PAR-4, cancer

Author for correspondence:

Juha Klefström
e-mail: juha.klefstrom@helsinki.fi

[†]These authors contributed equally to this study.

Breaking the epithelial polarity barrier in cancer: the strange case of LKB1/PAR-4

Johanna I. Partanen[†], Topi A. Tervonen[†] and Juha Klefström

Cancer Cell Circuitry Laboratory, Translational Cancer Biology Research Program and Institute of Biomedicine, University of Helsinki, Biomedicum Helsinki, Rm B507b, PO Box 63, Haartmaninkatu 8, 00014 Helsinki, Finland

The PAR clan of polarity regulating genes was initially discovered in a genetic screen searching for genes involved in asymmetric cell divisions in the *Caenorhabditis elegans* embryo. Today, investigations in worms, flies and mammals have established PAR proteins as conserved and fundamental regulators of animal cell polarization in a broad range of biological phenomena requiring cellular asymmetries. The human homologue of invertebrate PAR-4, a serine–threonine kinase LKB1/STK11, has caught attention as a gene behind Peutz–Jeghers polyposis syndrome and as a bona fide tumour suppressor gene commonly mutated in sporadic cancer. LKB1 functions as a master regulator of AMP-activated protein kinase (AMPK) and 12 other kinases referred to as the AMPK-related kinases, including four human homologues of PAR-1. The role of LKB1 as part of the energy sensing LKB1-AMPK module has been intensively studied, whereas the polarity function of LKB1, in the context of homeostasis or cancer, has gained less attention. Here, we focus on the PAR-4 identity of LKB1, discussing the weight of evidence indicating a role for LKB1 in regulation of cell polarity and epithelial integrity across species and highlight recent investigations providing new insight into the old question: does the PAR-4 identity of LKB1 matter in cancer?

1. Introduction

The famous narrative from the Scottish author Robert Louis Stevenson, *The Strange Case of Dr Jekyll and Mr Hyde*, keeps inspiring not only those fascinated by psychiatric split personality disorder but also cell biologists working on multi-functional proteins. In this sense, the tumour suppressor protein LKB1/ PAR-4 is a strange case. The LKB1 identity of this kinase protein, also known as serine/threonine kinase 11 (STK11), has been associated with upstream activation of the two isoforms of AMP-activated protein kinase (AMPK) and 12 AMPK-related kinases (ARKs). Doubtless, LKB1 is a key regulator of cell metabolism. However, LKB1/STK11 has yet another identity because the protein is a human homologue of PAR-4, a member of a PAR clan of proteins involved in regulation of cell polarity in worms, flies and mammals. Which, among the multiple identities of a single protein LKB1/STK11/PAR-4, is then Dr Henry Jekyll and which is the evil Mr Edward Hyde? The answer is obvious: none is Mr Hyde because cells do not express evil proteins. However, it appears that the bad nature of Mr Hyde surfaces on the pathways that suffer from loss of LKB1. Inheriting a mutated copy of the LKB1 gene predisposes to autosomal-dominant Peutz–Jeghers polyposis syndrome (PJS) and multiple cancers. LKB1 is also mutated in a variety of sporadic cancers. When cells lose LKB1, they also lose a mechanism to activate AMPK. Without AMPK activity, cells are not capable of controlling the mammalian target-of-rapamycin (mTOR) pathway, and consequently cells lose their grip on growth control and proliferation. This chapter about LKB1 is almost like something from the Stevenson story—Dr Jekyll is not inherently a good person but he is not acting like Mr Hyde because he is able to repress impulses, which feed the savage behaviour of Mr Hyde. How does the loss of PAR-4 identity become visible in tumour-prone cells that have lost LKB1? Investigations in flies and mammals have shown that cells without PAR-4 (LKB1) activity suffer from an inability to maintain apico-basal polarity and to sustain integrity of cell–cell

junctions, including apical junctions. Damage at apical tight junctions in these cells may be a deed of Mr Hyde, because loss of cell cohesion promotes invasion of the cancer cells into neighbouring tissues. However, we posit in this review that one witnesses the true savageness of Mr Hyde in a ferocious assault that PAR-4-derepressed pathways launch against the basal side of the cells. The attack shatters the basement membrane using a transmembrane serine protease called Hepsin—akin to the heavy cane that Mr Hyde uses to beat his first victim to death. Basement membrane is the last line that cancer cells have to cross before they can invade connective tissue.

We first introduce here a few basic concepts of cell polarity and epithelial integrity, discussing how impaired control of these mechanisms may promote tumorigenesis. Thereafter, we focus on LKB1, discussing the relevance of the PAR-4 identity of LKB1 in polarity regulation and cancer.

2. Loss of epithelial polarity in cancer: an epiphenomenon or a cause?

Epithelial tissues vary in form and function, but the basic principle of apico-basal polarity is similar in different tissues. In polarized epithelial cells, the apical surface is oriented towards the lumen or external environment. This side of the epithelial cell, which often has membrane protrusions (microvilli), takes care of the absorption, exchange and secretion of molecules and macromolecules [1]. Lateral surfaces of the epithelial cells contact adjacent cells via specialized cell–cell junctions, namely tight junctions, adhesion junctions and desmosomes. On the opposite side of the apical membrane is the basal surface, which anchors cells to a basement membrane. Basement membrane is a thin (about 100 nm), dense sheet composed of a meshwork of insoluble molecules including laminin polymers, a cross-linked network of collagen IV fibrils, proteoglycans and glycoproteins [2,3].

(a) Epithelial cell polarity: frame and function

Polarized membranes and cytosolic molecular asymmetries are fundamentally important for epithelial cells to function as a multi-cellular organized tissue. The molecular asymmetries guide directional exocytosis and secretion of digestive enzymes from pancreas, milk from mammary epithelium and vectorial transfer of nutrients across the gut epithelium to blood [1]. Furthermore, extension of epithelial monolayers requires that cell divisions occur in the plane of the sheet and many key cell polarity proteins are involved in determining alignment of the mitotic spindle so that it is perpendicular to the axis of apico-basal polarity [4–6]. In addition to many proteins, lipids are also asymmetrically distributed in polarized cells [1]. In particular, the asymmetric distribution of phosphatidylinositol phosphates Ptd(4,5)P₂ (PIP₂) and Ptd(3,4,5)P₃ (PIP₃) along the apico-basal axis, observed in several cell types, has been attributed to the differential activities of PTEN phosphatases and PtdIns3-kinases (PI3K) on the apical and basolateral sides of cells [1,7,8]. Developing (primordial) adhesion junctions, tight junctions, desmosomes and basal cell surface–basement membrane contacts provide landmarks and orientation cues for development of apico-basal cell polarity [1,9]. Tight junctions maintain the polarized status of membrane domains by physically restricting lateral

diffusion of integral membrane proteins. Also, key cadherins of adhesion junctions and desmosomes, E-cadherin and desmocollin, are necessary for proper formation of cell polarity and organization of epithelial structures [10]. Furthermore, there is evidence indicating that hemidesmosomes, which are structures attaching the basal surface of the cells to the underlying basement membrane at irregular intervals, are important for development of polarized epithelial architecture [11]. At the basal side of the cells, interference of β 1-integrin contact with laminin can even invert the apico-basal polarity so that the apical surface becomes oriented towards the matrix [12]. The vesicular trafficking pathways, which are often guided by distinct cytoskeletal tracks, are important cellular machineries for maintenance of polarity as they direct and recycle plasma membrane proteins specifically to the apical membrane and basement membrane [9,13,14]. For example, synthesis of functionally active basement membrane requires both polarized localization of plasma membrane proteins, for example integrins, and polarized secretion of basement membrane proteins, for example laminins [3,15].

In *Drosophila* and mammals, the apical identity of apico-basally polarized cells is maintained and regulated by two conserved polarity complexes (named according to gene names), the CRB/PALS1/PATJ (Crb) complex and the PAR3/PAR6/aPKC (Par) complex. On basolateral sides of the cells, a module of Scrib, Dlg and Lgl proteins controls the basolateral identity [16]. Scrib, Dlg and Lgl physically interact with each other in *Drosophila* epithelial cells, forming a Scrib complex, whereas in mammalian cells, the nature of these interactions is less clear. The core molecular machinery that generates cellular asymmetry is conserved from worms to mammals. The main components of the machinery are six (or five depending on species) functionally, but not structurally, related PAR (for ‘partitioning defective’) proteins [17]. The core set of PAR proteins, which is discussed in §3, along with a limited number of other proteins such as aPKC and CDC42, is involved in a broad range of phenomena requiring cellular polarization, such as apico-basal polarity, neurite extension, cellular migration and asymmetric cell division.

(b) Epithelial cell polarity: collapse in cancer

Cancer progression from benign tumour (local mass of cells) to invasive and metastatic cancer features loss of all aforementioned characteristics of polarized epithelial cells. Indeed, loss of organized epithelial structure, loss of cell polarity and loss of basement membrane attachment are among the key diagnostic criteria that differentiate benign tumours from life-threatening malignant cancers. One could envision that collapse of the polarity system benefits the process of cancer progression in many ways (figure 1). For example, erratic alignment of the mitotic spindle could enable efficient expansion of a cell mass in every direction, thus promoting hyperplasia. Out-of-alignment mitotic spindle may also increase aneuploidy [5,23]. Altered cell adhesion and extracellular matrix-dependent signalling mechanisms may make cells more migratory [24], loss of lipid asymmetry may deregulate spatial PI3K signalling and any cell-intrinsic (e.g. loss of cues for directional secretion) or -extrinsic mechanism harming basal polarity could lead to deterioration of basement membrane, thus paving the way to invasion and metastasis [24,25]. Thus, in general, the aforementioned qualities would




Figure 1. Loss of epithelial integrity—a hallmark of all advanced cancers. A schematic of cellular level changes, which typify disintegration of epithelial structure during tumour progression. Partial or complete loss of basement membrane (BM) is a defining diagnostic marker to distinguish the *in situ* type of carcinoma from invasive carcinoma [18]. Loss of cell–cell junctions, for example via loss of E-cadherin, is a common feature associating with the epithelial–mesenchymal transition [19,20]. Junctional complexes are also altered so that adhesive cell–cell junctions are loosened and migratory focal adhesions increased [19]. Loss of epithelial cell polarity associates with deterioration of cell junctions and basement membrane, as discussed in this review, which enhances the proliferative potential and migratory capacity of epithelial cells [21]. However, the cell polarity machinery cannot be completely demolished in cancer, because the core polarity machinery is necessary not only for apico-basal polarity but also for cell migration [22]. Thus, evolving cancers may need to carefully select polarity targets so as to acquire benefits from loss of apico-basal polarity but not to compromise ability to proliferate or migrate.

benefit arising tumours by cutting off cell structures, which stabilize organized epithelial structure (cell–cell adhesions, basement membrane), and endowing cells with new migratory capacities to move out of epithelial organizations and into the stroma.

The polarized phenotype of epithelial cells is lost when a tumour progresses towards malignancy, but it is still unclear whether there are specific and prevalent genetic mutations that contribute to tumour progression because they disrupt epithelial cell polarity. So far, experiments in *Drosophila* provide the strongest evidence for a causal role of polarity genes in tumour progression. The genes of the Scrib complex form the core of *Drosophila* neoplastic tumour suppressor genes (nTSGs) and, beyond nTSGs, inactivation of almost any core gene of the polarity machinery, for example *bazooka* (equivalent of human PAR3), *stardust* (similar to human PALS1) and *cdc42*, dramatically promotes metastatic behaviour of Ras or Raf-initiated tumours [16,26,27].

However, these findings in *Drosophila* may not directly translate into human cancers, because many recently published reports cataloguing the most frequently mutated genes

across thousands of human cancer genomes do not feature polarity genes at the top of the lists. Our own investigation to estimate the frequency of somatic mutations in polarity genes, several years ago, suggested that these mutations are indeed rare [21]. The rarity of mutations in core polarity genes, however, does not mean that cell polarity would be an irrelevant concept in cancer. In mammals, genetic redundancy efficiently buffers against deleterious effects of single-gene mutations, and there are commonly multiple homologues corresponding to prototypic *Drosophila* polarity genes [28]. This means that, in mammals, tumour microevolution could preferentially single out non-redundant polarity genes (rather than the most typical) as targets for polarity-damaging mutations. It is also worth noting that recent focused screens on cancer cell lines for small intragenic deletions have identified hitherto missed mutations in polarity genes, for example in PAR3, paving the way for more precise analysis of polarity-gene mutations in heterogenous primary tumour material [29]. Further evidence supporting the role of polarity genes as potential tumour suppressor genes comes from the findings that several core polarity genes, for example Dlg and Scrib,

are targeted for degradation by oncogenic human papilloma-viruses [30]. Finally, in mouse models of human cancer, like in *Drosophila* models of tumour progression, a cell polarity gene deficiency (LKB1/PAR4, SCRIB, PAR3) can dramatically promote tumorigenesis in tissues engineered to express a dominantly acting oncogene, such as Myc or Ras [31–34].

The role of core polarity genes and surrounding regulatory networks in cancer has been recently comprehensively covered in many reviews. This emerging field of research continues to inspire investigators as it holds promise for identifying novel, fundamentally important pathways contributing to tumour progression and invasion as well as new therapies to fight cancer [7,9,34–36]. This review focuses on liver kinase B1, serine–threonine kinase 11 (LKB1/STK11), which is a human homologue of PAR-4. LKB1 has the strongest link to cancer among the PAR proteins but it is also a multi-functional protein with a number of other functions, besides polarity regulation.

3. The LKB1 tumour suppressor gene: PAR-4 and more

The LKB1 gene is the only human homologue of *Caenorhabditis elegans* par-4 and *Drosophila* lkb1, encoding a serine–threonine kinase with multiple functions in regulation of cell polarity, metabolism and cell growth [37–39]. LKB1 is known as the critical upstream kinase required for the activation of AMPK, which is a cellular energy sensor and central regulator of cell metabolism. The LKB1-AMPK module also operates via the mTOR pathway to regulate cell growth [38]. These aspects of LKB1 signalling and links of the pathways to cancer have been covered in a number of recent reviews [37–39]. Below, we review the incidence of LKB1 mutations in cancer and discuss the PAR-4 identity of LKB1, illuminating functions and signalling of LKB1 in the context of physiological regulation of cell polarity and epithelial tissue integrity.

(a) LKB1 in hereditary and sporadic tumours

Germline mutations in tumour suppressor LKB1 lead to autosomal-dominant PJS, characterized by benign hamartomatous polyps occurring throughout the gastrointestinal tract [40–42]. Patients with PJS also have a significantly increased risk of developing cancer, for example, in the gastrointestinal tract, pancreas, breast and ovaries [43–45].

Different types of sporadic cancers also harbour somatic mutations in the LKB1 genes. Most frequently, LKB1 mutations have been found in non-small cell lung carcinoma. In this cancer type, more than 30% of the cases have somatic and homozygous inactivating mutations in LKB1 [46,47]. Somatic LKB1 mutations are also common in cervical cancer, found in about 20% of cases [48]. In addition, LKB1 mutations have been observed in melanomas and cancers of the pancreas, liver, breast and endometrium, although at reduced frequency [49–53]. Reduced or missing expression of Lkb1 has been reported in a range of cancers, including endometrial, pancreatic and breast cancer [49,54–56]. In breast cancer, LKB1 mutations appear to be rare, but loss of expression is common based on the results from tissue microarrays and Western blot analysis of tumours [32,54]. Loss of LKB1 expression has been attributed to epigenetic silencing mechanisms, including promoter hypermethylation

in breast cancer, and there is also some evidence that reduced LKB1 levels correlate with poor prognosis in these cancers [54,57,58]. In melanoma, posttranslational inactivation mechanisms may target LKB1 because mutated B-RAF leads to phosphorylation of LKB1, which inhibits it from activating downstream targets [59].

(b) LKB1 as a polarity protein PAR-4

The PAR (partitioning defective) set of polarity regulating proteins was initially found through a screen searching for mutants that disrupt the first asymmetric cell divisions in the *C. elegans* embryo [60]. PAR-4, the *C. elegans* homologue of LKB1, was among the six PAR genes found necessary for cytoplasmic partitioning and asymmetric cell division in the worm zygote (figure 2). Subsequent studies have exposed PAR proteins as fundamental regulators of cell polarization in diverse animals and different contexts of polarity [17]. The core PAR proteins are a diverse group of proteins: PAR-1 and PAR-4 encode serine–threonine kinases, PAR-5 belongs to the 14-3-3 family of proteins, which are recruited to phosphorylate serines and threonines. PAR-3 and PAR-6 contain PDZ domains, which are signalling and protein interaction scaffolds, and PAR-2 has a RING finger domain that may be used in the ubiquitination pathway. PAR proteins 1, 2, 3 and 6 acquire asymmetric localization patterns during the development of cell polarization in *C. elegans*, whereas PAR-4 remains symmetrically localized in cortex and cytoplasm during the process [17]. Interestingly from the LKB1 perspective, epistatic analyses have demonstrated that PAR-4 is essential for establishment of PAR-3/PAR-6 asymmetry, suggesting that PAR-4 may master-regulate the asymmetric segregation of other PAR family proteins [40,61].

In *Drosophila* (figure 2), PAR-4/lkb1 is required for the formation of early antero-posterior polarity in oocytes and epithelial apico-basal polarity in follicle cells [62]. In adult *Drosophila* retinal cells, inactivation of *lkb1* also leads to disruption of polarity and further disarrangement of cell–cell junctions and membrane domains [63]. The signalling circuitries, which in flies may operate downstream of *lkb1* in epithelial polarity regulation, are discussed below.

In mammalian cells (figure 2), construction of a STRAD adaptor protein-mediated system to ectopically activate LKB1 by Baas *et al.* [64] led to a surprising finding that activation of LKB1 is sufficient to polarize single, isolated intestinal epithelial cells in culture—a finding that challenged current views of the importance of cell–cell contacts in the process of polarization. Subsequent descriptive and functional studies have pictured LKB1 as a cell-polarity-linked protein in various contexts of mammalian tissue asymmetries. For example, LKB1 has been implicated in polarization of mouse oocytes [65]. Furthermore, LKB1 is required for axon specification during polarization of cortical neurons [66,67] and it participates in the formation of Sertoli cell polarity and testicular junctions [68].

Recent studies from our laboratory have also suggested that LKB1 is crucial for the integrity of mammary epithelial tissue [32,69]. A detailed analysis of three-dimensional cultures of primary mouse mammary epithelial cells (MMECs), rendered LKB1 deficient by adenoviral Cre infection, shows that loss of LKB1 disorganizes the normally rounded phenotype of acinus-like structures. Characteristic of LKB1-deficient structures is lateralized or completely mislocalized expression of apical polarity markers. In an electron microscopic analysis,




Figure 2. LKB1/PAR-4 in regulation of cell polarity. LKB1 functions as a PAR-4 cell polarity gene in *C. elegans*, *Drosophila* and mammalian epithelial and neuronal cells. Highlighted are suggested downstream targets, through which LKB1 may regulate cell polarity in different systems.

the LKB1-deficient three-dimensional structures show multiple abnormalities in desmosomes and tight junctions as well as deteriorated basement membrane. A selective deletion of LKB1 in the adult mammary gland, obtained by crossing mice with floxed LKB1 alleles with mice harbouring a lactogenic hormone-inducible WAP-Cre construct leads to many similar phenotypes observed in the *in vitro* three-dimensional cultures. The LKB1-deficient mammary ductal and alveolar structures express a disorganized pattern of apical markers and incomplete basement membrane as well as displaying enhanced branching of the ducts [32]. However, inactivation of LKB1 may lead to strikingly different phenotypes in different epithelial tissues as discussed next.

(c) LKB1 and epithelial tissue morphogenesis

The basic architecture of epithelial tubes in all branching organs, for example, kidney, mammary gland, lung and blood vessels, is a polarized epithelium that apically faces a central luminal space and basally contacts basement membrane [70]. The mechanisms of branching are complex and vary between different tissue types, but the main underpinnings of the branching process are coordinated actions between proliferation, apico-basal polarity and epithelial motility machineries. Several investigations have also highlighted the role of basement membrane as a scaffold providing cues for reorientation of polarity during the branching process as well as incomplete basement membrane coverage at branching points as an element regulating branching morphogenesis [70].

Recent investigations have coupled LKB1 to branching morphogenesis in two different organs—lung and the mammary gland. The study of Lo *et al.* [71], using an ATP-binding pocket modified form of LKB1 that confers sensitivity to specific inhibition by a small molecule ATP analogue, shows that inactivation of the modified LKB1 inhibits branching morphogenesis of embryonic lung tissue in an *ex vivo* explant culture. The branching defect was rescued by activation of AMPK, suggesting a role for the LKB1-AMPK pathway in the branching process. The same study also shows that the phenotypic

effects resulting from inactivation of LKB1 are tissue- and context-specific. In pancreatic tissue, chemical inactivation of LKB1 results in development of cystic structures by mechanisms not involving defective AMPK signalling.

In the study of Partanen *et al.*, conditional deletion of LKB1 genes, *ex vivo*, in three-dimensional organoids and, *in vivo*, in the mammary gland, leads to hyperbranching of the mammary ducts. In the mammary gland, loss of LKB1 simultaneously leads to defects in cell polarity, cell junctions and basement membranes [32]. In the study of Lo *et al.* [71], polarity defects were not observed in embryonic lung tissue after inactivation of LKB1. Therefore, it is possible that the hyperbranching phenotype results from loss of polarity and incomplete basement membrane coverage, and in tissues spared from these defects, LKB1 loss may have other, even opposite effects.

(d) LKB1/PAR-4 signalling pathways in epithelial polarity

The kinase activity of LKB1 in mammalian cells requires the formation of a heterotrimeric complex consisting of LKB1, pseudokinase Ste20-related adaptor protein (STRAD) and a scaffold protein, for example mouse protein 25 (MO25) [72,73]. Binding to STRAD and MO25 renders LKB1 active and furthermore, regulates stability and localization of LKB1 protein [73,74]. LKB1 functions as a master regulator of the two isoforms of AMPK (AMPK- α 1 and AMPK- α 2) and 12 other kinases referred to as the ARKs [75–78]. All LKB1-regulated downstream kinases, AMPK and ARKs, require LKB1-dependent phosphorylation in the threonine 172 (T172) (or equivalent residue) that resides in the activation loop to become active. The AMPK and ARK serine–threonine kinases belong to a small subfamily of calcium/calmodulin-dependent protein kinases comprising AMPK- α 1 and AMPK- α 2, four MARK/PAR-1 kinases (MARK1–4), the AMPK-related kinase 5 (ARK5, NUAK1), the SNF/AMPK-related kinase (SNARK, NUAK2), two Brain-specific kinases (BRSK1 and 2), three

salt-induced kinases or SIKs (SIK1/SIK, SIK2/QIK and SIK3/QSK) and the Snf-related serine/threonine kinase (SNRK) [76].

Among the LKB1 downstream kinases, AMPKs, MARK/ PAR-1 kinases and BRSK1 and 2 have been linked to regulation of cell polarity in a context-dependent manner (figure 2). Findings in *Drosophila* have suggested that LKB1 may use AMPK to signal cell polarity [79]. In *Drosophila* follicular epithelial cells, *ampk-α* null mutants exhibit normal epithelial polarity in a nutrient-rich environment but in culture media deprived of sugars, conditions where AMPK normally is maximally active, apico-basal cell polarity of these cells is disrupted. Also *lkb1* mutants show similar energy-starvation-dependent polarity defects, which can be rescued by a constitutively active AMPK transgene [79]. Another study has shown that downstream of the *ampk-α* mutation, a constitutively active form of a protein non-muscle myosin regulatory light chain (MRLC or MLC2) rescues the polarity defects of *ampk-α* mutant cells [80]. These investigations altogether suggest that at least in flies, the LKB1-AMPK-MRLC module regulates cell polarity in a mode that is responsive to cues from cellular energy status. In mammals, branching defects in embryonic lung tissue, caused by LKB1 inactivation, can be rescued via ectopic activation of AMPK [71]. In cultured mammalian cells, AMPK has also been shown to play a role in cell polarity and formation of tight junctions [81,82].

Mammalian microtubule-associated protein (MAP)/ microtubule affinity-regulating kinases (MARKs) are homologues of *C. elegans* PAR-1, which was identified in the same *C. elegans* partitioning defective screen as LKB1/PAR-4 [60]. PAR-1 serine/threonine kinase regulates other PAR proteins to establish cell polarity. For instance, in *Drosophila*, PAR-1 phosphorylates PAR-3 to retain it in the apical pole of the oocyte [83]. In mammals, MARK2 (PAR1b) has been implicated as a downstream effector of LKB1 in regulation of apico-basal polarity of pancreatic acinar cells *in vivo* [84]. Recently, it was found that MARK2 physically associates with a RhoA-specific guanine nucleotide exchange factor, influencing RhoA activity and the actin cytoskeleton. This interaction could couple PAR-1-dependent polarity regulation to cell movement [85]. The virulence factor CagA in *Helicobacter pylori* cagA-positive strains interacts with MARKs/PAR1 causing junctional and polarity defects. It is believed that this interaction leads to the disorganization of epithelial architecture and loss of epithelial barrier function observed in *Helicobacter*-infected gastric epithelium [86]. MARKs may also regulate cell polarity by phosphorylating MAPs, for example tau, and that type of interaction is important for polarized protein trafficking [87,88].

In neuronal cells, polarization is important for axonal and dendritic specification that is fundamental to the ability of neuronal cells to transmit information. LKB1 has been linked to regulation of polarized migration of neurons and to promotion of axon initiation during neuronal polarization through downstream kinases BRSK1 and -2 (also known as SAD-A and -B), which in turn may contribute to cell polarity via phosphorylation of MAPs [66,67,89].

4. Loss of PAR-4 identity matters in cancer: evil deeds on the basal side of the epithelial cells

As discussed in the beginning of this review, collapse of a cell polarity system can benefit cancer progression in multiple

ways. However, among the pillars of epithelial integrity, the basement membrane is the last barrier to resist invasion of motile cancer cells into the neighbouring tissues. Therefore, any cell-intrinsic or -extrinsic mechanism harming the integrity or altering the biological activity of basement membrane could promote invasion and progression to metastatic disease [24,25,90]. Loss of LKB1 has been shown to influence the biological activity of basement membrane via non-proteolytic and proteolysis-dependent mechanisms. The functional interaction between LKB1 loss and type II transmembrane proteases may also involve polarity regulation.

(a) LKB1 and non-proteolytic moulding of basement membrane

A stiffening of the extracellular matrix, which is attributable to increased or inappropriate cross-linking of collagens, contributes to increased migratory and invasive behaviour of cancer cells and is considered one indicator of poor cancer prognosis [91–93]. One contributing factor to matrix stiffening is enhanced activity of lysyl-oxidases (LOX), enzymes that play an important physiological role in strengthening collagen fibrils, including type IV collagen of basement membrane, via covalent cross-linking of lysine residues in these proteins [93]. A functional role of LOX in cancer has been addressed by blocking LOX activity, which reduces tumour incidence in the MMTV-Neu mouse model of breast cancer [93]. Loss-of-function mutations in LKB1 are common in lung cancer and loss of LKB1 has been observed to correlate with significantly enhanced levels of LOX enzymes. In a mouse model of lung cancer and human non-small cell lung cancer cell lines, loss of LKB1 leads via enhanced mTOR and HIF1α signalling to enhanced LOX activity, increased deposition of collagen and enhanced proliferation possibly caused by increased matrix stiffness [94]. Thus, although the physiological significance of LKB1–LOX crosstalk remains unclear, loss of LKB1 and the consequent dysregulation of LOX activity in the context of tumour tissue has a prominent impact on stromal extracellular matrix remodelling and collagen biology (figure 3).

(b) LKB1 and proteolytic moulding of basement membrane

(i) LKB1 and metalloproteinases

Matrix metalloproteinases (MMPs) are a group of enzymes able to degrade various extracellular matrix and cell surface molecules, aiding in tissue remodelling and branching morphogenesis. The activity of MMPs is commonly elevated in cancers [95–97]. However, whether these enzymes specifically contribute to degradation of collagen IV, a basement membrane transmigration-limiting factor [98], is unclear although MMP-2 and MMP-9 have been implicated in the process [95,99]. In a study, LKB1 overexpression has been shown to correlate with downregulation of MMP-2 and MMP-9 and invasion inhibition in an *in vitro* assay as well as with the tumorigenicity and metastasizing capacity of xenografted tumour cells [100]. However, the significance of these findings in the context of LKB1 inactivation remains to be determined.

(ii) LKB1 and type II transmembrane serine proteases

In our study, using mice with LKB1-deficient mammary glands, we found evidence that basement membrane may




Figure 3. A model: loss of LKB1 and basement membrane remodelling. Mammary epithelial cells are bound to each other via tight junctions, adherens junctions and desmosomes. A TTSP hepsin is expressed on the basal and lateral membranes of epithelial cells, exhibiting a colocalized expression pattern with desmosomes. Loss of LKB1 inflicts damage to tight junctions and desmosomes, which associate with widespread loss of epithelial integrity. In the present model (modified from Partanen [32]), this damage liberates hepsin from the membranes into the cytosol. Hepsin is commonly overexpressed in cancer (an effect that can be seen in cells engineered to overexpress MYC), and we posit that the overexpressed and mislocalized hepsin causes deterioration of basement membrane (BM). Breakdown of BM is considered an essential step for tumour invasion and metastases. However, loss of LKB1 may also exert opposite, stabilizing effects on BMs and extracellular matrix by stimulating expression of the collagen cross-linking enzyme LOX [94]. Also, these effects may benefit tumour progression, at least once the tumour has breached the BM barrier, by increasing the stiffness of the extracellular matrix. Stiff matrix stimulates tumour cell proliferation and, in some instances, migration. The investigations expose the complex nature of functional interactions between LKB1 and constituents of extracellular matrix, which may inhibit or facilitate tumorigenesis depending on context.

be degraded by type II transmembrane serine proteases (TTSPs) during mammary tumorigenesis [32]. We reported that loss of LKB1 does not induce palpable tumours during the lifetime of the mice but leads to mild abnormalities in the mammary gland, such as hyperbranching, partial disorganization of apical polarity and incomplete basement membrane. However, combining LKB1 deficiency with oncogenic MYC dramatically accelerates the appearance of mammary tumours in comparison with glands exposed to oncogenic MYC alone [32]. The study shows that both MYC⁺ and MYC⁺;LKB1⁻ tumours are histopathologically mostly adenocarcinomas and not informative as such regarding the possible mechanisms underlying accelerated tumorigenesis. However, the histology of hyperplastic regions in between tumour areas was particularly interesting, providing a path for follow-up studies. Expression of oncogenic MYC alone, a stimulus known to promote cell proliferation, had led to development of surplus ductal branches and alveolar units. All structures generated under the influence of MYC were separated from stroma and neighbouring epithelial structures by basement membranes. By contrast, the hyperplastic regions in the MYC⁺;LKB1⁻ mammary glands had surplus epithelial cells but mostly unrecognizable ductal or alveolar epithelial structures. In the hyperplastic regions of MYC⁺;LKB1⁻ mammary glands, the bordering basement membranes were missing giving the impression that epithelial structures were fused together into

a huge disorganized cell mass. Missing basement membrane was a defining difference between the hyperplastic glands expressing oncogenic MYC (basement membrane present) and those expressing MYC combined with loss of LKB1 (basement membrane absent).

Investigating MMECs, isolated from aforementioned mice, in *ex vivo* three-dimensional cultures, we observed that MYC⁺ epithelial structures were hyperplastic but still maintained the rounded morphology. By contrast, the MYC⁺;LKB1⁻ structures showed extensive branching and lacked basement membrane components, such as nidogen and collagen IV [32]. A panel of small molecule inhibitors tested in a rescue assay did not support specific roles for MMPs, but instead suggested involvement of TTSPs in deterioration of basement membrane. Subsequent studies identified a strong correlation between loss of LKB1 and overexpression of a TTSP called hepsin/TMPRSS1 in our transgenic mouse models and in a panel of 60 clinical human breast cancer samples. Knock-down of hepsin rescued basement membrane in MYC⁺;LKB1⁻ three-dimensional structures, indicating a role for hepsin in basement membrane degradation [32].

While the question of whether, downstream from LKB1 loss, hepsin-mediated deterioration of basement membrane promotes mammary tumorigenesis has not been addressed, the oncogenicity of hepsin has been investigated specifically in prostate cancer models. Hepsin originally caught the

attention of cancer researchers in microarray profiling studies, who found almost ubiquitous overexpression of hepsin in prostate cancer [101,102]. Nearly 90% of prostate cancers over-express mRNA for hepsin with up to 30-fold levels compared with normal prostate tissue. Profound hepsin overexpression is also found in ovarian and breast cancers, and high hepsin mRNA levels are commonly accompanied by strong hepsin protein signal in tumour sections [32,103–106]. A mouse model engineered to express hepsin under probasin promoter in prostate has revealed widespread defects in the integrity of hemidesmosomes and basement membrane, indicating deleterious interaction between hepsin overexpression and basement membrane *in vivo* [107]. *In vitro*, the targets for the proteolytic activity of hepsin include the major basal laminal component laminin-332 [108]. Basement membrane degradation is a critical step for initiation of cancer metastasis, and evidence from transgenic and orthotopic tumourgraft models of prostate and ovarian cancer suggest that overexpression of hepsin can promote incidence of metastases [104,107,109]. However, the relationship between LKB1-deficiency and hepsin overexpression in prostate cancer has not yet been systematically studied. According to the data obtained from the Wellcome Trust Sanger Institute Cancer Genome Project web site, <http://www.sanger.ac.uk/genetics/CGP> (COSMIC and CONAN), LKB1 mutations have been found in prostate cancer cell lines and with less than 1% frequency in prostate cancer but to our knowledge, the epigenetic influences on gene expression levels have not yet been addressed in prostate cancer.

(c) Hepsin: permanent desmosome resident or a cleaver-wielding bandit on the loose

It is still unclear how mechanistically overexpression of hepsin damages basement membrane, but investigations on the localization of hepsin in normal and transformed cells, and changes in this localization in response to oncogenic signalling may provide some clues. In non-transformed and some transformed cells, the transmembrane protease hepsin localizes to cell membranes, its protease domain pointing to the pericellular space [110]. In ovarian cancer cells and primary MMEC, the immunostaining pattern of hepsin prominently overlaps with desmosomal proteins [32,104]. Desmosomes are junctional complexes mediating the attachment of specific cell-surface adhesion proteins, desmogleins and desmocollins, to intracellular intermediate filaments. In general, tumours express either a membranous or cytosolic pattern of hepsin depending on the type and grade of the tumours [32,101,104,105].

Absence of critical desmosomal proteins, for instance desmoplakin, or depletion of desmoplakin in response to LKB1 inactivation leads to translocation of hepsin from cell–cell borders to cytosol [32,104]. In ovarian cancer cells, also, the ectopically overexpressed hepsin is mainly cytosolic [104]. Therefore, it can be hypothesized that hepsin is normally sequestered to desmosomes but if the junctional integrity is compromised, as in most cancer cells, hepsin becomes liberated in the cytosol (figure 3). It still remains a mystery how cytosolic hepsin interacts with basement membrane but it is interesting to note that vesicular trafficking plays an important role in the activation cascades of other TTSPs. A TTSP family member, matriptase has been reported to activate a downstream TTSP prostasin on the basolateral membrane of polarized colonic

epithelial cells from which activated prostasin is intracellularly transcytosed to apical membrane of the cells [111]. It is tempting to speculate that loss of cues for directional secretion in depolarized cancer cells perturbs cell polarity-coupled proteolytic cascades. Hence, disruption of polarity could lead to uncontrolled proteolytic attacks on different cellular domains, including basement membranes.

Finally, in addition to causing physical damage to basement membrane, overexpressed (or liberated) hepsin may also contribute to tumour progression via remodelling of basement membrane, which is not only a barrier but also a dynamic scaffold that controls access of the cells to various growth factors. For example, proteoglycans bind and sequester growth factors and cytokines, regulating their availability to cells [112,113]. Moreover, basement membrane proteins often contain cryptic sites, which are exposed after extracellular matrix digestion and can consequently act as pro-migratory, pro-invasive or angiogenic cues [2,114]. Hepsin can proteolytically activate many factors in the microenvironment of epithelial cells, including hepatocyte growth factor, urokinase-type plasminogen activator, macrophage-stimulating protein and EGF receptor, all of which are well-known players in cancer [110,115–120].

5. Conclusion: lessons learned and challenges ahead

Common interest in regulation and dysregulation of cell polarity in health and disease has recently brought together biologists with diverse backgrounds, representing single cell and invertebrate models, developmental and neurobiology, and cancer biology. In particular, past studies in *Drosophila*, revealing how potentially loss-of-gene functions involved in cell polarity and epithelial integrity promote tumorigenesis, have spurred interest in the polarity pathways among cancer biologists. However, it is clear that the evolutionary distance and gene diversification between flies and humans makes it challenging to directly relate tumour genetics in flies to human cancer. For example, it is still a matter of debate whether the closest human structural homologues of fly nTSGs are prevalent in human tumour suppressor genes. While the ongoing studies on human versions of nTSGs are expected to shed light on the question, it is also emerging that the PAR clan of proteins plays an important role at the intersection of polarity regulation and tumour suppression in mammals. PAR-4/LKB1 is the clan member with a strongest link to cancer but the multiple functions of LKB1 makes it challenging to discern the role of the PAR-4 identity of LKB1 in tumorigenesis. PAR-4 also does not have asymmetric localization in cells, in contrast to for example apical PAR-3 and PAR-6, which makes it difficult to distinguish between apical and basal polarity-directed actions of PAR-4/LKB1. However, current studies have indicated evidence that loss of PAR-4/LKB1 weakens apical cell–cell cohesion and launches hepsin-mediated proteolytic and LOX involving non-proteolytic pathways to digest and remodel the basement membrane on the basal side of the cells as well as extracellular matrix—all of these events promote the spread of cancer cells from epithelial structures to connective tissue. While this evidence supports the involvement of the PAR-4 identity in tumour development, a strong case also exists to convict the LKB1-AMPK-mTOR branch of involvement in tumorigenesis. On which side does the burden of

proof lie? According to current knowledge, LKB1 predominantly signals via AMPK and the PAR-4 identity of LKB1 signals via activation of PAR1 (MARKs). However, how separate these identities in fact are is a question that will deserve closer inspection. PAR-1/MARK proteins belong to a family of ARKs and, in addition, evidence exists from studies in flies and mammals indicating the involvement of LKB1-AMPK axis in polarity regulation. The possibility that metabolic pathways interact with polarity pathways, or vice versa, warrants further studies as an area of obvious interest and significance to epithelial biology. This takes us back to Stevenson's novella, *The Strange Case of Dr Jekyll and Mr Hyde*. At the end of the story, the line between the different identities of Dr Jekyll and Mr Hyde becomes blurred when Dr Jekyll keeps metamorphosing into Hyde involuntarily and Hyde seeks a potion to revert back to Dr Jekyll again. If

this chapter holds to the strange case of LKB1/PAR-4, future research will identify not only isolated phenotypes attributed to LKB1/PAR-4 but also signalling nodes linking different LKB1/PAR-4 regulated networks and cellular phenotypes. Such nodes would be prime targets for therapeutic potions aiming to change evil Hyde back to Jekyll again.

Acknowledgements. We thank all the members of Klefström laboratory for discussions and, in particular, Dr Elsa Marques for critical comments on the manuscript.

Funding statement. This study was financially supported by the Academy of Finland and National Technology Agency TEKES, Sigrid Jusélius Foundation and Finnish Cancer Organizations and Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115188, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007–2013) and the European Federation of Pharmaceutical Industries and Associations.

References

- Bryant DM, Mostov KE. 2008 From cells to organs: building polarized tissue. *Nat. Rev. Mol. Cell Biol.* **9**, 887–901. (doi:10.1038/nrm2523)
- Kalluri R. 2003 Basement membranes: structure, assembly and role in tumour angiogenesis. *Nat. Rev. Cancer* **3**, 422–433. (doi:10.1038/nrc1094)
- Yurchenco PD. 2011 Basement membranes: cell scaffoldings and signaling platforms. *Cold Spring Harb. Perspect. Biol.* **3**, 1–27. (doi:10.1101/cshperspect.a004911)
- Durgan J, Kaji N, Jin D, Hall A. 2011 Par6B and atypical PKC regulate mitotic spindle orientation during epithelial morphogenesis. *J. Biol. Chem.* **286**, 12 461–12 474. (doi:10.1074/jbc.M110.174235)
- Hao Y, Du Q, Chen X, Zheng Z, Balsbaugh JL, Maitra S, Shabanowitz J, Hunt DF, Macara IG. 2010 Par3 controls epithelial spindle orientation by aPKC-mediated phosphorylation of apical Pins. *Curr. Biol.* **20**, 1809–1818. (doi:10.1016/j.cub.2010.09.032)
- Lu MS, Johnston CA. 2013 Molecular pathways regulating mitotic spindle orientation in animal cells. *Development* **140**, 1843–1856. (doi:10.1242/dev.087627)
- Martin-Belmonte F, Mostov K. 2008 Regulation of cell polarity during epithelial morphogenesis. *Curr. Opin. Cell Biol.* **20**, 227–234. (doi:10.1016/j.cob.2008.01.001)
- Gassama-Diagne A, Yu W, ter Beest M, Martin-Belmonte F, Kierbel A, Engel J, Mostov K. 2006 Phosphatidylinositol-3,4,5-trisphosphate regulates the formation of the basolateral plasma membrane in epithelial cells. *Nat. Cell Biol.* **8**, 963–970. (doi:10.1038/ncb1461)
- Tervonen TA *et al.* 2011 Faulty epithelial polarity genes and cancer. *Adv. Cancer Res.* **111**, 97–161. (doi:10.1016/B978-0-12-385524-4.00003-9)
- Runswick SK, O'Hare MJ, Jones L, Streuli CH, Garrod DR. 2001 Desmosomal adhesion regulates epithelial morphogenesis and cell positioning. *Nat. Cell Biol.* **3**, 823–830. (doi:10.1038/ncb0901-823)
- Weaver VM, Lelievre S, Lakin JN, Chrenek MA, Jones JC, Giancotti F, Werb Z, Bissell MJ. 2002 β 4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. *Cancer Cell.* **2**, 205–216. (doi:10.1016/S1535-6108(02)00125-3)
- Yu W, Datta A, Leroy P, O'Brien LE, Mak G, Jou TS, Matlin KS, Mostov KE, Zegers MM. 2005 β 1-integrin orients epithelial polarity via Rac1 and laminin. *Mol. Biol. Cell* **16**, 433–445. (doi:10.1091/mbc.E04-05-0435)
- Orlando K, Guo W. 2009 Membrane organization and dynamics in cell polarity. *Cold Spring Harb. Perspect. Biol.* **1**, a001321. (doi:10.1101/cshperspect.a001321)
- Mellman I, Nelson WJ. 2008 Coordinated protein sorting, targeting and distribution in polarized cells. *Nat. Rev. Mol. Cell Biol.* **9**, 833–845. (doi:10.1038/nrm2525)
- Aumailley M, Pesch M, Tunggal L, Gaill F, Fassler R. 2000 Altered synthesis of laminin 1 and absence of basement membrane component deposition in (beta)1 integrin-deficient embryoid bodies. *J. Cell Sci.* **113**, 259–268.
- Bilder D. 2004 Epithelial polarity and proliferation control: links from the *Drosophila* neoplastic tumor suppressors. *Genes Dev.* **18**, 1909–1925. (doi:10.1101/gad.1211604)
- Goldstein B, Macara IG. 2007 The PAR proteins: fundamental players in animal cell polarization. *Dev. Cell* **13**, 609–622. (doi:10.1016/j.devcel.2007.10.007)
- Polyak K. 2010 Molecular markers for the diagnosis and management of ductal carcinoma in situ. *J. Natl Cancer Inst. Monogr.* **2010**, 210–213. (doi:10.1093/jncimonographs/lgq019)
- Canel M, Serrels A, Frame MC, Brunton VG. 2013 E-cadherin-integrin crosstalk in cancer invasion and metastasis. *J. Cell Sci.* **126**, 393–401. (doi:10.1242/jcs.100115)
- Scheel C, Weinberg RA. 2012 Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. *Semin. Cancer Biol.* **22**, 396–403. (doi:10.1016/j.semcancer.2012.04.001)
- Partanen JI, Nieminen AI, Klefstrom J. 2009 3D view to tumor suppression: Lkb1, polarity and the arrest of oncogenic c-Myc. *Cell Cycle* **8**, 716–724. (doi:10.4161/cc.8.5.7786)
- Humbert PO, Dow LE, Russell SM. 2006 The Scribble and Par complexes in polarity and migration: friends or foes? *Trends Cell Biol.* **16**, 622–630. (doi:10.1016/j.tcb.2006.10.005)
- Pease JC, Tirnauer JS. 2011 Mitotic spindle misorientation in cancer: out of alignment and into the fire. *J. Cell Sci.* **124**, 1007–1016. (doi:10.1242/jcs.081406)
- Muschler J, Streuli CH. 2010 Cell-matrix interactions in mammary gland development and breast cancer. *Cold Spring Harb. Perspect. Biol.* **2**, a003202. (doi:10.1101/cshperspect.a003202)
- Egeblad M, Nakasone ES, Werb Z. 2010 Tumors as organs: complex tissues that interface with the entire organism. *Dev. Cell* **18**, 884–901. (doi:10.1016/j.devcel.2010.05.012)
- Brumby AM, Richardson HE. 2003 Scribble mutants cooperate with oncogenic Ras or Notch to cause neoplastic overgrowth in *Drosophila*. *EMBO J.* **22**, 5769–5779. (doi:10.1093/emboj/cdg548)
- Pagliarini RA, Xu T. 2003 A genetic screen in *Drosophila* for metastatic behavior. *Science* **302**, 1227–1231. (doi:10.1126/science.1088474)
- Assemet E, Bazellieres E, Pallesi-Pocachard E, Le Bivic A, Massey-Harroche D. 2008 Polarity complex proteins. *Biochim. Biophys. Acta* **1778**, 614–630. (doi:10.1016/j.bbame.2007.08.029)
- Rothenberg SM *et al.* 2010 A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. *Cancer Res.* **70**, 2158–2164. (doi:10.1158/0008-5472.CAN-09-3458)
- Banks L, Pim D, Thomas M. 2012 Human tumour viruses and the deregulation of cell polarity in cancer. *Nat. Rev. Cancer* **12**, 877–886. (doi:10.1038/nrc3400)
- Leung CT, Brugge JS. 2012 Outgrowth of single oncogene-expressing cells from suppressive

- epithelial environments. *Nature* **482**, 410–413. (doi:10.1038/nature10826)
32. Partanen JI *et al.* 2012 Tumor suppressor function of Liver kinase B1 (Lkb1) is linked to regulation of epithelial integrity. *Proc. Natl Acad. Sci. USA* **109**, E388–E397. (doi:10.1073/pnas.1120421109)
 33. Zhan L, Rosenberg A, Bergami KC, Yu M, Xuan Z, Jaffe AB, Allred C, Muthuswamy SK. 2008 Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. *Cell* **135**, 865–878. (doi:10.1016/j.cell.2008.09.045)
 34. McCaffrey LM, Montalbano J, Mihai C, Macara IG. 2012 Loss of the Par3 polarity protein promotes breast tumorigenesis and metastasis. *Cancer Cell* **22**, 601–614. (doi:10.1016/j.ccr.2012.10.003)
 35. Lee M, Vasioukhin V. 2008 Cell polarity and cancer: cell and tissue polarity as a non-canonical tumor suppressor. *J. Cell Sci.* **121**, 1141–1150. (doi:10.1242/jcs.016634)
 36. Huang L, Muthuswamy SK. 2010 Polarity protein alterations in carcinoma: a focus on emerging roles for polarity regulators. *Curr. Opin. Genet. Dev.* **20**, 41–50. (doi:10.1016/j.gde.2009.12.001)
 37. Hardie DG, Alessi DR. 2013 LKB1 and AMPK and the cancer-metabolism link - ten years after. *BMC Biol.* **11**, 36. (doi:10.1186/1741-7007-11-36)
 38. Shaw RJ. 2009 LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. *Acta Physiol.* **196**, 65–80. (doi:10.1111/j.1748-1716.2009.01972.x)
 39. Jansen M, Ten Klooster JP, Offerhaus GJ, Clevers H. 2009 LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism. *Physiol. Rev.* **89**, 777–798. (doi:10.1152/physrev.00026.2008)
 40. Katajisto P, Vallenius T, Vahtomeri K, Ekman N, Udd L, Tiainen M, Makela TP. 2007 The LKB1 tumor suppressor kinase in human disease. *Biochim. Biophys. Acta* **1775**, 63–75. (doi:10.1016/j.bbcan.2006.08.003)
 41. Aretz S *et al.* 2005 High proportion of large genomic STK11 deletions in Peutz–Jeghers syndrome. *Hum. Mutat.* **26**, 513–519. (doi:10.1002/humu.20253)
 42. Hemminki A *et al.* 1998 A serine/threonine kinase gene defective in Peutz–Jeghers syndrome. *Nature* **391**, 184–187. (doi:10.1038/34432)
 43. Hearle N *et al.* 2006 STK11 status and intussusception risk in Peutz–Jeghers syndrome. *J. Med. Genet.* **43**, e41. (doi:10.1136/jmg.2005.040535)
 44. Mehenni H, Resta N, Park JG, Miyaki M, Guanti G, Costanza MC. 2006 Cancer risks in LKB1 germline mutation carriers. *Gut* **55**, 984–990. (doi:10.1136/gut.2005.082990)
 45. Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJ, Gittelsohn AM, Booker SV, Krush AJ, Yardley JH, Luk GD. 1987 Increased risk of cancer in the Peutz–Jeghers syndrome. *N. Engl. J. Med.* **316**, 1511–1514. (doi:10.1056/NEJM198706113162404)
 46. Gill RK *et al.* 2011 Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. *Oncogene* **30**, 3784–3791. (doi:10.1038/onc.2011.98)
 47. Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM, Westra WH, Herman JG, Sidransky D. 2002 Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. *Cancer Res.* **62**, 3659–3662.
 48. Wingo SN *et al.* 2009 Somatic LKB1 mutations promote cervical cancer progression. *PLoS ONE* **4**, e5137. (doi:10.1371/journal.pone.0005137)
 49. Contreras CM *et al.* 2008 Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. *Cancer Res.* **68**, 759–766. (doi:10.1158/0008-5472.CAN-07-5014)
 50. Forster LF, Defes S, Goudie DR, Baty DU, Carey FA. 2000 An investigation of the Peutz–Jeghers gene (LKB1) in sporadic breast and colon cancers. *J. Clin. Pathol.* **53**, 791–793. (doi:10.1136/jcp.53.10.791)
 51. Guldberg P, Thor Straten P, Ahrenkiel V, Seremet T, Kirkin AF, Zeuthen J. 1999 Somatic mutation of the Peutz–Jeghers syndrome gene, LKB1/STK11, in malignant melanoma. *Oncogene* **18**, 1777–1780. (doi:10.1038/sj.onc.1202486)
 52. Kim CJ *et al.* 2004 Genetic analysis of the LKB1/STK11 gene in hepatocellular carcinomas. *Eur. J. Cancer* **40**, 136–141. (doi:10.1016/S0959-8049(03)00659-2)
 53. Su GH *et al.* 1999 Germline and somatic mutations of the STK11/LKB1 Peutz–Jeghers gene in pancreatic and biliary cancers. *Am. J. Pathol.* **154**, 1835–1840. (doi:10.1016/S0002-9440(10)65440-5)
 54. Fenton H, Carlile B, Montgomery EA, Carraway H, Herman J, Sahin F, Su GH, Argani P. 2006 LKB1 protein expression in human breast cancer. *Appl. Immunohistochem. Mol. Morphol.* **14**, 146–153. (doi:10.1097/01.pai.0000176157.07908.20)
 55. Morton JP *et al.* 2010 LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. *Gastroenterology* **139**, e581–e586. (doi:10.1053/j.gastro.2010.04.055)
 56. Sahin F, Maitra A, Argani P, Sato N, Maehara N, Montgomery E, Goggins M, Hruban RH, Su GH. 2003 Loss of Stk11/Lkb1 expression in pancreatic and biliary neoplasms. *Mod. Pathol.* **16**, 686–691. (doi:10.1097/01.MP.0000075645.97329.86)
 57. Esteller M, Avizienyte E, Corn PG, Lothe RA, Baylin SB, Aaltonen LA, Herman JG. 2000 Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz–Jeghers syndrome. *Oncogene* **19**, 164–168. (doi:10.1038/sj.onc.1203227)
 58. Shen Z, Wen XF, Lan F, Shen ZZ, Shao ZM. 2002 The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma. *Clin. Cancer Res.* **8**, 2085–2090.
 59. Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, Chin L, Cantley LC. 2009 Oncogenic B-Raf negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. *Mol. Cell* **33**, 237–247. (doi:10.1016/j.molcel.2008.12.026)
 60. Kempthues KJ, Priess JR, Morton DG, Cheng NS. 1988 Identification of genes required for cytoplasmic localization in early *C. elegans* embryos. *Cell* **52**, 311–320. (doi:10.1016/S0092-8674(88)80024-2)
 61. Hung TJ, Kempthues KJ. 1999 PAR-6 is a conserved PDZ domain-containing protein that colocalizes with PAR-3 in *Caenorhabditis elegans* embryos. *Development* **126**, 127–135.
 62. Martin SG, St Johnston D. 2003 A role for Drosophila LKB1 in anterior-posterior axis formation and epithelial polarity. *Nature* **421**, 379–384. (doi:10.1038/nature01296)
 63. Amin N, Khan A, St Johnston D, Tomlinson I, Martin S, Brenman J, McNeill H. 2009 LKB1 regulates polarity remodeling and adherens junction formation in the *Drosophila* eye. *Proc. Natl Acad. Sci. USA* **106**, 8941–8946. (doi:10.1073/pnas.0812469106)
 64. Baas AF, Kuipers J, van der Wel NN, Battle E, Koerten HK, Peters PJ, Clevers HC. 2004 Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. *Cell* **116**, 457–466. (doi:10.1016/S0092-8674(04)00114-X)
 65. Szczepanska K, Maleszewski M. 2005 LKB1/PAR4 protein is asymmetrically localized in mouse oocytes and associates with meiotic spindle. *Gene Expr. Patterns* **6**, 86–93. (doi:10.1016/j.modgep.2005.04.013)
 66. Barnes AP, Lilley BN, Pan YA, Plummer LJ, Powell AW, Raines AN, Sanes JR, Polleux F. 2007 LKB1 and SAD kinases define a pathway required for the polarization of cortical neurons. *Cell* **129**, 549–563. (doi:10.1016/j.cell.2007.03.025)
 67. Shelly M, Cancedda L, Heilshorn S, Sumbre G, Poo MM. 2007 LKB1/STRAD promotes axon initiation during neuronal polarization. *Cell* **129**, 565–577. (doi:10.1016/j.cell.2007.04.012)
 68. Tanwar PS, Kaneko-Tarui T, Zhang L, Teixeira JM. 2012 Altered LKB1/AMPK/TSC1/TSC2/mTOR signaling causes disruption of Sertoli cell polarity and spermatogenesis. *Hum. Mol. Genet.* **21**, 4394–4405. (doi:10.1093/hmg/ddc272)
 69. Partanen JI, Nieminen AI, Makela TP, Klefstrom J. 2007 Suppression of oncogenic properties of c-Myc by LKB1-controlled epithelial organization. *Proc. Natl Acad. Sci. USA* **104**, 14 694–14 699. (doi:10.1073/pnas.0704677104)
 70. Andrew DJ, Ewald AJ. 2010 Morphogenesis of epithelial tubes: insights into tube formation, elongation, and elaboration. *Dev. Biol.* **341**, 34–55. (doi:10.1016/j.ydbio.2009.09.024)
 71. Lo B, Strasser G, Sagolla M, Austin CD, Junttila M, Mellman I. 2012 Lkb1 regulates organogenesis and early oncogenesis along AMPK-dependent and -independent pathways. *J. Cell. Biol.* **199**, 1117–1130. (doi:10.1083/jcb.201208080)
 72. Baas AF, Boudeau J, Sapkota GP, Smit L, Medema R, Morrice NA, Alessi DR, Clevers HC. 2003 Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. *EMBO J.* **22**, 3062–3072. (doi:10.1093/emboj/cdg292)
 73. Boudeau J, Baas AF, Deak M, Morrice NA, Kieloch A, Schutkowski M, Prescott AR, Clevers HC, Alessi DR. 2003 MO25 α/β interact with STRAD α/β enhancing their ability to bind, activate and localize

- LKB1 in the cytoplasm. *EMBO J.* **22**, 5102–5114. (doi:10.1093/emboj/cdg490)
74. Dorfman J, Macara IG. 2008 STRADalpha regulates LKB1 localization by blocking access to importin- α , and by association with Crm1 and exportin-7. *Mol. Biol. Cell* **19**, 1614–1626. (doi:10.1091/mbc.E07-05-0454)
 75. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, Alessi DR, Hardie DG. 2003 Complexes between the LKB1 tumor suppressor, STRAD α/β and MO25 α/β are upstream kinases in the AMP-activated protein kinase cascade. *J. Biol.* **2**, 28. (doi:10.1186/1475-4924-2-28)
 76. Lizcano JM *et al.* 2004 LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. *EMBO J.* **23**, 833–843. (doi:10.1038/sj.emboj.7600110)
 77. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, Cantley LC. 2004 The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. *Proc. Natl Acad. Sci. USA* **101**, 3329–3335. (doi:10.1073/pnas.0308061100)
 78. Woods A *et al.* 2003 LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. *Curr. Biol.* **13**, 2004–2008. (doi:10.1016/j.cub.2003.10.031)
 79. Mirouse V, Swick LL, Kazgan N, St Johnston D, Brenman JE. 2007 LKB1 and AMPK maintain epithelial cell polarity under energetic stress. *J. Cell Biol.* **177**, 387–392. (doi:10.1083/jcb.200702053)
 80. Lee JH *et al.* 2007 Energy-dependent regulation of cell structure by AMP-activated protein kinase. *Nature* **447**, 1017–1020. (doi:10.1038/nature05828)
 81. Zhang L, Li J, Young LH, Caplan MJ. 2006 AMP-activated protein kinase regulates the assembly of epithelial tight junctions. *Proc. Natl Acad. Sci. USA* **103**, 17 272–17 277. (doi:10.1073/pnas.0608531103)
 82. Zheng B, Cantley LC. 2007 Regulation of epithelial tight junction assembly and disassembly by AMP-activated protein kinase. *Proc. Natl Acad. Sci. USA* **104**, 819–822. (doi:10.1073/pnas.0610157104)
 83. Morton DG, Shakes DC, Nugent S, Dichoso D, Wang W, Golden A, Kempthues KJ. 2002 The *Caenorhabditis elegans* par-5 gene encodes a 14-3-3 protein required for cellular asymmetry in the early embryo. *Dev. Biol.* **241**, 47–58. (doi:10.1006/dbio.2001.0489)
 84. Granot Z *et al.* 2009 LKB1 regulates pancreatic beta cell size, polarity, and function. *Cell Metab.* **10**, 296–308. (doi:10.1016/j.cmet.2009.08.010)
 85. Yamahashi Y, Saito Y, Murata-Kamiya N, Hatakeyama M. 2011 Polarity-regulating kinase partitioning-defective 1b (PAR1b) phosphorylates guanine nucleotide exchange factor H1 (GEF-H1) to regulate RhoA-dependent actin cytoskeletal reorganization. *J. Biol. Chem.* **286**, 44 576–44 584. (doi:10.1074/jbc.M111.267021)
 86. Saadat I *et al.* 2007 *Helicobacter pylori* CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity. *Nature* **447**, 330–333. (doi:10.1038/nature05765)
 87. Tassan JP, Le Goff X. 2004 An overview of the KIN1/PAR-1/MARK kinase family. *Biol. Cell* **96**, 193–199. (doi:10.1016/j.biolcel.2003.10.009)
 88. Matenia D, Mandelkow EM. 2009 The tau of MARK: a polarized view of the cytoskeleton. *Trends Biochem. Sci.* **34**, 332–342. (doi:10.1016/j.tibs.2009.03.008)
 89. Asada N, Sanada K, Fukada Y. 2007 LKB1 regulates neuronal migration and neuronal differentiation in the developing neocortex through centrosomal positioning. *J. Neurosci.* **27**, 11 769–11 775. (doi:10.1523/JNEUROSCI.1938-07.2007)
 90. Valastyan S, Weinberg RA. 2011 Tumor metastasis: molecular insights and evolving paradigms. *Cell* **147**, 275–292. (doi:10.1016/j.cell.2011.09.024)
 91. Frantz C, Stewart KM, Weaver VM. 2010 The extracellular matrix at a glance. *J. Cell Sci.* **123**, 4195–4200. (doi:10.1242/jcs.023820)
 92. Lu P, Weaver VM, Werb Z. 2012 The extracellular matrix: a dynamic niche in cancer progression. *J. Cell Biol.* **196**, 395–406. (doi:10.1083/jcb.201102147)
 93. Levental KR *et al.* 2009 Matrix crosslinking forces tumor progression by enhancing integrin signaling. *Cell* **139**, 891–906. (doi:10.1016/j.cell.2009.10.027)
 94. Gao Y *et al.* 2010 LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. *Proc. Natl Acad. Sci. USA* **107**, 18 892–18 897. (doi:10.1073/pnas.1004952107)
 95. Hotary K, Li XY, Allen E, Stevens SL, Weiss SJ. 2006 A cancer cell metalloprotease triad regulates the basement membrane transmigration program. *Genes Dev.* **20**, 2673–2686. (doi:10.1101/gad.1451806)
 96. Liotta LA, Kleinerman J, Catanzaro P, Rynbrandt D. 1977 Degradation of basement membrane by murine tumor cells. *J. Natl Cancer Inst.* **58**, 1427–1431.
 97. Sternlicht MD, Werb Z. 2001 How matrix metalloproteinases regulate cell behavior. *Annu. Rev. Cell Dev. Biol.* **17**, 463–516. (doi:10.1146/annurev.cellbio.17.1.463)
 98. Rowe RG, Weiss SJ. 2008 Breaching the basement membrane: who, when and how? *Trends Cell Biol.* **18**, 560–574. (doi:10.1016/j.tcb.2008.08.007)
 99. Page-McCaw A, Ewald AJ, Werb Z. 2007 Matrix metalloproteinases and the regulation of tissue remodelling. *Nat. Rev. Mol. Cell Biol.* **8**, 221–233. (doi:10.1038/nrm2125)
 100. Zhuang ZG, Di GH, Shen ZZ, Ding J, Shao ZM. 2006 Enhanced expression of LKB1 in breast cancer cells attenuates angiogenesis, invasion, and metastatic potential. *Mol. Cancer Res.* **4**, 843–849. (doi:10.1158/1541-7786.MCR-06-0118)
 101. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. 2001 Delineation of prognostic biomarkers in prostate cancer. *Nature* **412**, 822–826. (doi:10.1038/35090585)
 102. Webb SL, Sanders AJ, Mason MD, Jiang WG. 2011 Type II transmembrane serine protease (TTSP) deregulation in cancer. *Front. Biosci.* **16**, 539–552. (doi:10.2741/3704)
 103. Tanimoto H, Yan Y, Clarke J, Korourian S, Shigemasa K, Parmley TH, Parham GP, O'Brien TJ. 1997 Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. *Cancer Res.* **57**, 2884–2887.
 104. Miao J, Mu D, Ergel B, Singavarapu R, Duan Z, Powers S, Oliva E, Orsulic S. 2008 Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model. *Int. J. Cancer* **123**, 2041–2047. (doi:10.1002/ijc.23726)
 105. Xing P, Li JG, Jin F, Zhao TT, Liu Q, Dong HT, Wei XL. 2011 Clinical and biological significance of hepsin overexpression in breast cancer. *J. Invest. Med.* **59**, 803–810. (doi:10.2311/JIM.0b013e31821451a1)
 106. Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyrtos F, Cohen P, Lidereau R, Bieche I. 2006 Identification of novel genes that co-cluster with estrogen receptor α in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. *Endocr. Relat. Cancer* **13**, 1109–1120. (doi:10.1677/erc.1.01120)
 107. Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. 2004 Hepsin promotes prostate cancer progression and metastasis. *Cancer Cell* **6**, 185–195. (doi:10.1016/j.ccr.2004.07.008)
 108. Tripathi M, Nandana S, Yamashita H, Ganesan R, Kirchhofer D, Quaranta V. 2008 Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression. *J. Biol. Chem.* **283**, 30 576–30 584. (doi:10.1074/jbc.M802312200)
 109. Li W *et al.* 2009 Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis. *Cancer Res.* **69**, 8395–8402. (doi:10.1158/0008-5472.CAN-09-1995)
 110. Antalí TM, Buzza MS, Hodge KM, Hooper JD, Netzel-Arnett S. 2010 The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment. *Biochem. J.* **428**, 325–346. (doi:10.1042/BJ20100046)
 111. Friis S, Godiksen S, Bornholdt J, Selzer-Plon J, Rasmussen HB, Bugge TH, Lin CY, Vogel LK. 2011 Transport via the transcytotic pathway makes prostaticin available as a substrate for matriptase. *J. Biol. Chem.* **286**, 5793–5802. (doi:10.1074/jbc.M110.186874)
 112. Iozzo RV, Sanderson RD. 2011 Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. *J. Cell. Mol. Med.* **15**, 1013–1031. (doi:10.1111/j.1582-4934.2010.01236.x)
 113. Mongiat M, Taylor K, Otto J, Aho S, Uitto J, Whitelock JM, Iozzo RV. 2000 The protein core of the proteoglycan perlecan binds specifically to fibroblast growth factor-7. *J. Biol. Chem.* **275**, 7095–7100. (doi:10.1074/jbc.275.10.7095)
 114. Iozzo RV, Zoeller JJ, Nystrom A. 2009 Basement membrane proteoglycans: modulators *par excellence* of cancer growth and angiogenesis. *Mol. Cells* **27**, 503–513. (doi:10.1007/s10059-009-0069-0)
 115. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. 1997 The urokinase-type plasminogen activator system in cancer metastasis: a review. *Int. J. Cancer* **72**, 1–22. (doi:10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z)

116. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. 2003 Met, metastasis, motility and more. *Nat. Rev. Mol. Cell Biol.* **4**, 915–925. (doi:10.1038/nrm1261)
117. Foley J, Nickerson NK, Nam S, Allen KT, Gilmore JL, Nephew KP, Riese II DJ. 2010 EGFR signaling in breast cancer: bad to the bone. *Semin. Cell Dev. Biol.* **21**, 951–960. (doi:10.1016/j.semcdb.2010.08.009)
118. Ganesan R, Kolumam GA, Lin SJ, Xie MH, Santell L, Wu TD, Lazarus RA, Chaudhuri A, Kirchhofer D. 2011 Proteolytic activation of pro-macrophage-stimulating protein by hepsin. *Mol. Cancer Res.* **9**, 1175–1186. (doi:10.1158/1541-7786.MCR-11-0004)
119. Welm AL, Sneddon JB, Taylor C, Nuyten DS, van de Vijver MJ, Hasegawa BH, Bishop JM. 2007 The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. *Proc. Natl Acad. Sci. USA* **104**, 7570–7575. (doi:10.1073/pnas.0702095104)
120. Chen M, Chen LM, Lin CY, Chai KX. 2010 Hepsin activates prostaticin and cleaves the extracellular domain of the epidermal growth factor receptor. *Mol. Cell Biochem.* **337**, 259–266. (doi:10.1007/s11010-009-0307-y)